Physician profile
Daniel M Sleiter
NPI 1447242359
$43,690.45
in general payments reported to CMS, 2019-2025
15 companies · $92.85 in 2025
The $92.85 reported for 2025 was less than what a typical Pediatrics (Nurse Practitioner) provider received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20K · 2022: $24K · 2023: $25.65 · 2025: $92.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $118.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $24,191.82 | 2021-2022 | |
| Dexcom, INC. | $18,017.57 | 2021-2022 | |
| Abbott Laboratories | $787.79 | 2021-2023 | Freestyle Libre 2 |
| Abbvie INC. | $149.74 | 2021-2022 | |
| Ascendis Pharma Endocrinology INC | $142.75 | 2022 | |
| Sequel Med Tech, LLC | $92.85 | 2025 | Twiist |
| Novo Nordisk INC | $73.81 | 2021-2022 | |
| Mannkind Corporation | $72.42 | 2022 | |
| Lilly USA, LLC | $43.60 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $33.30 | 2022 | |
| Alexion Pharmaceuticals, INC. | $20.66 | 2022 | |
| Insulet Corporation | $18.41 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $16.69 | 2022 | |
| Zealand Pharma US, INC. | $15.03 | 2021 | |
| Xeris Pharmaceuticals, INC. | $14.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Sleiter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.